Generic pain, margin loss: Drug companies may find it hard to adjust with Trump's tariff plans

US President Trump's 25% tariff plan on pharmaceuticals jeopardizes Indian pharma exports, making generics pricier and impacting margins. Indian companies and stock markets brace for the impact, as India dominates with 30% of exports to the US. Firms may face challenges balancing costs and profit margins.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SfajAUJ
via IFTTT